-
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 June 07, 2026 19:30 ET | Source: LENZ Therapeutics, Inc. SAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ, “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine…
-
Francisco Ranzi Müller Leads the MicAi-X Technology Upgrade, Bringing Automated Trading Capabilities Into a New Cycle
SAN DIEGO, June 03, 2026 (GLOBE NEWSWIRE) — Recently, the automated trading program service platform MicAi-X has officially launched a new round of platform system upgrade plan. Founder and IT team leader Francisco Ranzi Müller will lead the relevant technical planning and system optimization efforts. This upgrade is regarded as a key milestone for MicAi-X…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
